Candin

BIOLOGICAL7 trials

Sponsors

Mark Hatherill, Nielsen BioSciences, Inc., Janssen Research & Development, LLC, Tonix Pharmaceuticals, Inc.

Conditions

Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2HIVHealthyTuberculosisWarts

Early Phase 1

A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy Participants

CompletedNCT03953196

Janssen Research & Development, LLCHealthy

Start: 2019-04-08End: 2019-12-26Updated: 2025-02-03

Phase 1

A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 1

CompletedNCT04589026

Janssen Research & Development, LLCHealthy

Start: 2020-10-21End: 2021-05-06Updated: 2025-02-03

A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 2

CompletedNCT04611971

Janssen Research & Development, LLCHealthy

Start: 2020-10-27End: 2021-05-06Updated: 2025-02-03

Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens

TerminatedNCT05216510

Tonix Pharmaceuticals, Inc.Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2

Start: 2022-01-07End: 2022-09-17Updated: 2024-11-06

A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 4

CompletedNCT05522517

Janssen Research & Development, LLCHealthy

Start: 2022-08-22End: 2022-11-02Updated: 2025-02-03

Phase 2

Safety and Immunogenicity of MVA85A Prime and Bacille Calmette-Guerin Boost Vaccination

CompletedNCT01650389

Mark HatherillHIV, Tuberculosis

Start: 2012-10-31End: 2015-05-31Updated: 2015-09-30

Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)

CompletedNCT02393417

Nielsen BioSciences, Inc.Warts

Start: 2015-03-31End: 2018-03-31Updated: 2019-06-04

Related Papers

Randomized Phase IIa Trial of Purified Candida Antigen for Common Warts: Evaluating the Safety and Efficacy Across Multiple Dosing Regimens

Dermatology and Therapy2025-03-291 citations

Interleukin-1α inhibitor bermekimab in patients with atopic dermatitis: randomized and nonrandomized studies.

2024-08-308 citations

Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial

Clinical Infectious Diseases2017-09-2235 citations